W R Hiatt

Summary

Affiliation: University of Colorado Health Sciences Center
Country: USA

Publications

  1. ncbi The US experience with cilostazol in treating intermittent claudication
    William R Hiatt
    Section of Vascular Medicine, Divisions of Geriatrics and Cardiology, University of Colorado, Health Sciences Center, Colorado Prevention Center, 789 Sherman Street, Suite 200, Denver, CO 80203, USA
    Atheroscler Suppl 6:21-31. 2005
  2. ncbi Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects)
    William R Hiatt
    Section of Vascular Medicine, Divisions of Geriatrics and Cardiology, University of Colorado School of Medicine C O Colorado Prevention Center, Denver, CO 80203, USA
    J Vasc Surg 47:330-336. 2008
  3. ncbi Carnitine and peripheral arterial disease
    William R Hiatt
    University of Colorado Health Sciences Center, Colorado Prevention Center, Denver, CO 80203, USA
    Ann N Y Acad Sci 1033:92-8. 2004
  4. ncbi Preventing atherothrombotic events in peripheral arterial disease: the use of antiplatelet therapy
    W R Hiatt
    Divisions of Geriatrics and Cardiology, Section of Vascular Medicine, University of Colorado Health Sciences Center and the Colorado Prevention Center, Denver, CO 80203, USA
    J Intern Med 251:193-206. 2002
  5. ncbi Treatment of disability in peripheral arterial disease: new drugs
    William R Hiatt
    Divisions of Geriatrics and Cardiology, Section of Vascular Medicine, University of Colorado Health Sciences Center and the Colorado Prevention Center, Denver, Colorado, USA
    Curr Drug Targets Cardiovasc Haematol Disord 4:227-31. 2004
  6. ncbi Randomized trial of AT-1015 for treatment of intermittent claudication. A novel 5-hydroxytryptamine antagonist with no evidence of efficacy
    William R Hiatt
    Department of Medicine, University of Colorado School of Medicine, Section of Vascular Medicine, and the Colorado Prevention Center, Denver, CO 80203, USA
    Vasc Med 9:18-25. 2004
  7. ncbi The effect of inhibition of acyl coenzyme A-cholesterol acyltransferase (ACAT) on exercise performance in patients with peripheral arterial disease
    William R Hiatt
    Section of Vascular Medicine, University of Colorado Health Sciences Center, 4200 E 9th Ave, Denver, CO 80262, USA
    Vasc Med 9:271-7. 2004
  8. ncbi Quality of the assessment of primary and secondary endpoints in claudication and critical leg ischemia trials
    William R Hiatt
    Colorado Prevention Center, University of Colorado Health Sciences Center, Denver, CO 80203, USA
    Vasc Med 10:207-13. 2005
  9. ncbi New drug application 21-628, Certican (everolimus), for the proposed indication of prophylaxis of rejection in heart transplantation: report from the Cardiovascular and Renal Drugs Advisory Committee, US Food and Drug Administration, November 16, 2005, Ro
    William R Hiatt
    Department of Medicine, University of Colorado Health Sciences Center, Denver, CO 80203, USA
    Circulation 113:e394-5. 2006
  10. ncbi Acute pharmacological conversion of atrial fibrillation to sinus rhythm: is short-term symptomatic therapy worth it? A report from the December 2007 Meeting of the Cardiovascular and Renal Drugs Advisory Committee of the Food and Drug Administration
    William R Hiatt
    University of Colorado Denver, School of Medicine, Denver, CO 80203, USA
    Circulation 117:2956-7. 2008

Detail Information

Publications71

  1. ncbi The US experience with cilostazol in treating intermittent claudication
    William R Hiatt
    Section of Vascular Medicine, Divisions of Geriatrics and Cardiology, University of Colorado, Health Sciences Center, Colorado Prevention Center, 789 Sherman Street, Suite 200, Denver, CO 80203, USA
    Atheroscler Suppl 6:21-31. 2005
    ..Based on the available evidence, a comprehensive approach to claudication management is recommended...
  2. ncbi Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects)
    William R Hiatt
    Section of Vascular Medicine, Divisions of Geriatrics and Cardiology, University of Colorado School of Medicine C O Colorado Prevention Center, Denver, CO 80203, USA
    J Vasc Surg 47:330-336. 2008
    ..At the time of approval, the United States Food and Drug Administration required an additional long-term safety study to evaluate the effect cilostazol on mortality...
  3. ncbi Carnitine and peripheral arterial disease
    William R Hiatt
    University of Colorado Health Sciences Center, Colorado Prevention Center, Denver, CO 80203, USA
    Ann N Y Acad Sci 1033:92-8. 2004
    ..The drug also improved quality of life and had minimal side effects as compared with placebo. Propionyl-L-carnitine has not been approved for use in the United States...
  4. ncbi Preventing atherothrombotic events in peripheral arterial disease: the use of antiplatelet therapy
    W R Hiatt
    Divisions of Geriatrics and Cardiology, Section of Vascular Medicine, University of Colorado Health Sciences Center and the Colorado Prevention Center, Denver, CO 80203, USA
    J Intern Med 251:193-206. 2002
    ..Aspirin and/or clopidogrel are the antiplatelet agents of choice for the reduction of atherothrombotic events in patients with PAD...
  5. ncbi Treatment of disability in peripheral arterial disease: new drugs
    William R Hiatt
    Divisions of Geriatrics and Cardiology, Section of Vascular Medicine, University of Colorado Health Sciences Center and the Colorado Prevention Center, Denver, Colorado, USA
    Curr Drug Targets Cardiovasc Haematol Disord 4:227-31. 2004
    ..These drugs also have an excellent safety profile. A final promising class of drugs is statins that not only reduce the increased risk of ischemic events but also appear to improve claudication symptoms...
  6. ncbi Randomized trial of AT-1015 for treatment of intermittent claudication. A novel 5-hydroxytryptamine antagonist with no evidence of efficacy
    William R Hiatt
    Department of Medicine, University of Colorado School of Medicine, Section of Vascular Medicine, and the Colorado Prevention Center, Denver, CO 80203, USA
    Vasc Med 9:18-25. 2004
    ..These data indicate that selective serotonin receptor blockade does not improve exercise tolerance or quality of life in individuals with claudication...
  7. ncbi The effect of inhibition of acyl coenzyme A-cholesterol acyltransferase (ACAT) on exercise performance in patients with peripheral arterial disease
    William R Hiatt
    Section of Vascular Medicine, University of Colorado Health Sciences Center, 4200 E 9th Ave, Denver, CO 80262, USA
    Vasc Med 9:271-7. 2004
    ....
  8. ncbi Quality of the assessment of primary and secondary endpoints in claudication and critical leg ischemia trials
    William R Hiatt
    Colorado Prevention Center, University of Colorado Health Sciences Center, Denver, CO 80203, USA
    Vasc Med 10:207-13. 2005
    ..Site interventions need to address these deficiencies in measurement to improve the quality of PAD trials...
  9. ncbi New drug application 21-628, Certican (everolimus), for the proposed indication of prophylaxis of rejection in heart transplantation: report from the Cardiovascular and Renal Drugs Advisory Committee, US Food and Drug Administration, November 16, 2005, Ro
    William R Hiatt
    Department of Medicine, University of Colorado Health Sciences Center, Denver, CO 80203, USA
    Circulation 113:e394-5. 2006
  10. ncbi Acute pharmacological conversion of atrial fibrillation to sinus rhythm: is short-term symptomatic therapy worth it? A report from the December 2007 Meeting of the Cardiovascular and Renal Drugs Advisory Committee of the Food and Drug Administration
    William R Hiatt
    University of Colorado Denver, School of Medicine, Denver, CO 80203, USA
    Circulation 117:2956-7. 2008
  11. ncbi Effect of niacin ER/lovastatin on claudication symptoms in patients with peripheral artery disease
    William R Hiatt
    Section of Vascular Medicine, Division of Geriatrics, University of Colorado Denver School of Medicine, Denver, CO 80203, USA
    Vasc Med 15:171-9. 2010
    ..6% on low niacin-statin (p = 0.096). Flushing as the most common event leading to discontinuation and treatment was associated with increases in liver enzymes, fasting blood glucose concentration and a decrease in platelet count...
  12. ncbi Masterclass series in peripheral arterial disease. Antiplatelet therapy for peripheral arterial disease and claudication
    William R Hiatt
    Department of Medicine, University of Colorado School of Medicine, Section of Vascular Medicine, Divisions of Geriatrics and Cardiology, Denver, Colorado 80203, USA
    Vasc Med 11:55-60. 2006
    ..The use of aspirin as well as more potent antiplatelet therapies such as thienopyridines holds promise for reducing atherothrombosis in this very high-risk population...
  13. ncbi Pharmacologic therapy for peripheral arterial disease and claudication
    William R Hiatt
    Department of Medicine, University of Colorado School of Medicine, c o Colorado Prevention Center, 789 Sherman Street, Suite 200, Denver, CO 80203, USA
    J Vasc Surg 36:1283-91. 2002
    ....
  14. ncbi Abnormal oxygen uptake kinetic responses in women with type II diabetes mellitus
    J G Regensteiner
    Section of Vascular Medicine, Department of Medicine, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    J Appl Physiol 85:310-7. 1998
    ..The findings may reflect impaired cardiac responses to exercise, although an additional defect in skeletal muscle oxygen diffusion or mitochondrial oxygen utilization is also possible...
  15. ncbi Current medical therapies for patients with peripheral arterial disease: a critical review
    Judith G Regensteiner
    Section of Vascular Medicine, Division of Internal Medicine, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Am J Med 112:49-57. 2002
    ....
  16. ncbi Intravenous L-carnitine increases plasma carnitine, reduces fatigue, and may preserve exercise capacity in hemodialysis patients
    E P Brass
    Department of Medicine, Harbor University of California at Los Angeles Medical Center, Torrance, CA 90509, USA
    Am J Kidney Dis 37:1018-28. 2001
    ..VO(2max) in the primary analysis and other assessed end points were unaffected by carnitine therapy...
  17. ncbi A randomized trial of iloprost in patients with intermittent claudication
    Mark A Creager
    Department of Medicine, Division of Cardiology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Vasc Med 13:5-13. 2008
    ..039). Neither iloprost nor pentoxifylline enhanced quality of life. These results indicate that oral iloprost is not effective in improving exercise performance or quality of life in patients with PAD who have intermittent claudication...
  18. ncbi Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes
    Philip S Mehler
    Internal Medicine at Denver Health and Hospitals, University of Colorado Health Sciences Center, Denver 80203, USA
    Circulation 107:753-6. 2003
    ..CONCLUSIONS: In PAD patients with diabetes, intensive blood pressure lowering to a mean of 128/75 mm Hg resulted in a marked reduction in cardiovascular events...
  19. ncbi Risk assessment in the patient with established peripheral arterial disease
    Scott Haugen
    Divisions of Cardiology and General Internal Medicine, Department of Medicine, University of Colorado School of Medicine, Denver, CO, USA
    Vasc Med 12:343-50. 2007
    ..Defining which patients are in the highest category of risk may direct health care providers to emphasize secondary preventive measures, and facilitate patient adherence to recommended medical therapies and smoking cessation...
  20. ncbi Effects of exercise training on oxygen uptake kinetic responses in women with type 2 diabetes
    S L Brandenburg
    Department of Medicine, University of Colorado Health Sciences Center, Denver 80262, USA
    Diabetes Care 22:1640-6. 1999
    ....
  21. ncbi Increased levels of apoptosis in gastrocnemius skeletal muscle in patients with peripheral arterial disease
    Robert G Mitchell
    Division of Cardiology, Department of Medicine, Durham VA and Duke University Medical Center, Durham, NC 27710, USA
    Vasc Med 12:285-90. 2007
    ..53% +/- 0.96; p < 0.001). In conclusion, PAD is associated with increased levels of apoptosis in the peripheral skeletal muscle. Further study is required to ascertain whether apoptosis plays a role in decreased functional capacity...
  22. ncbi Use of ankle brachial index screening for selecting patients for antiplatelet drug therapy
    Mori J Krantz
    Colorado Prevention Center, Denver, Colorado 80203, USA
    Pharmacotherapy 25:1826-8; discussion 1827-8. 2005
  23. ncbi Skeletal muscle metabolic changes in peripheral arterial disease contribute to exercise intolerance: a point-counterpoint discussion
    Eric P Brass
    Center for Clinical Pharmacology, Department of Medicine, Harbor-UCLA Medical Center, Torrance, CA, USA
    Vasc Med 9:293-301. 2004
    ..The relative contribution of these factors and their role in the pathophysiology of the exercise limitation is discussed using a point-counterpoint approach. Future directions for research conclude the discussion...
  24. ncbi Clinical outcomes using aggressive approach to anatomic screening and endovascular revascularization in a veterans affairs population with critical limb ischemia
    Alap P Shah
    Department of Medicine, University of Colorado Denver, Aurora, Colorado, USA
    Catheter Cardiovasc Interv 74:11-9. 2009
    ....
  25. ncbi Exercise training for claudication
    Kerry J Stewart
    Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, USA
    N Engl J Med 347:1941-51. 2002
  26. ncbi The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease
    Eric P Brass
    Department of Medicine, Harbor UCLA Medical Center, Torrance, California 90502, USA
    J Am Coll Cardiol 48:2539-45. 2006
    ..The current study tested the hypothesis that NM-702 improves treadmill exercise performance in peripheral arterial disease patients with claudication-limited exercise performance...
  27. ncbi Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication
    W R Hiatt
    Department of Medicine, Section of Vascular Medicine, Divisions of Geriatrics and Cardiology, University of Colorado Health Sciences Center, Denver 80203, USA
    Am J Med 110:616-22. 2001
    ..CONCLUSIONS: Propionyl-L-carnitine safely improved treadmill exercise performance and enhanced functional status in patients with claudication...
  28. ncbi Decreased NADH dehydrogenase and ubiquinol-cytochrome c oxidoreductase in peripheral arterial disease
    E P Brass
    Department of Medicine, Harbor University of California Los Angeles Medical Center, Torrance, California 90509, USA
    Am J Physiol Heart Circ Physiol 280:H603-9. 2001
    ....
  29. ncbi Skeletal muscle StO2 kinetics are slowed during low work rate calf exercise in peripheral arterial disease
    Timothy A Bauer
    Department of Medicine, University of Colorado at Denver Health Sciences Center, Box B 179, 4200 East Ninth Avenue, Denver, CO 80262, USA
    Eur J Appl Physiol 100:143-51. 2007
    ....
  30. ncbi Adjunctive parenteral therapy with lipo-ecraprost, a prostaglandin E1 analog, in patients with critical limb ischemia undergoing distal revascularization does not improve 6-month outcomes
    Mark R Nehler
    University of Colorado Health Sciences Center and the Colorado Prevention Center, Denver, CO 80262 0302, USA
    J Vasc Surg 45:953-60; discussion 960-1. 2007
    ....
  31. ncbi Treatment of peripheral arterial disease
    Judith G Regensteiner
    Divisions of Internal Medicine and Cardiology, University of Colorado Health Sciences Center, Denver, Colorado, USA
    Clin Cornerstone 4:26-40. 2002
    ..Although many therapies for claudication have been thoroughly investigated, research continues on new treatments. In contrast, more prospective, randomized trials are needed to evaluate various therapies for treating patients with PAD...
  32. ncbi Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials
    Judith G Regensteiner
    Department of Medicine, Division of Internal Medicine and Cardiology, The University of Colorado Health Sciences Center, Denver 80262, USA
    J Am Geriatr Soc 50:1939-46. 2002
    ....
  33. ncbi Peripheral arterial disease rehabilitation: a review
    Rita A Falcone
    Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    J Cardiopulm Rehabil 23:170-5. 2003
  34. ncbi Impaired muscle oxygen use at onset of exercise in peripheral arterial disease
    Timothy A Bauer
    University of Colorado Health Sciences Center, Denver 80262, USA
    J Vasc Surg 40:488-93. 2004
    ..Impaired muscle metabolism may contribute to the altered physiologic responses to exercise and to exercise impairment in patients with PAD...
  35. ncbi Functional outcome in a contemporary series of major lower extremity amputations
    Mark R Nehler
    University of Colorado Health Sciences Center, Department of Surgery, Vascular Surgery Section, Denver, CO 80262, USA
    J Vasc Surg 38:7-14. 2003
    ..We undertook this study to document the functional natural history of patients undergoing major amputation in an academic vascular surgery and rehabilitation medicine practice...
  36. ncbi Patterns of artery disease in 450 patients undergoing revascularization for critical limb ischemia: implications for clinical trial design
    Carlos A Rueda
    University of Colorado Health Sciences Center, Aurora, CO 80045, USA
    J Vasc Surg 47:995-9; discussion 999-1000. 2008
    ..The pattern and distribution of arterial occlusions and stenoses in patients with critical limb ischemia presenting at two academic medical centers was described...
  37. ncbi The impact of peripheral arterial disease on health-related quality of life in the Peripheral Arterial Disease Awareness, Risk, and Treatment: New Resources for Survival (PARTNERS) Program
    Judith G Regensteiner
    Department of Medicine, University of Colorado School of Medicine, Denver, CO 80262, USA
    Vasc Med 13:15-24. 2008
    ....
  38. ncbi Wound healing and functional outcomes after infrainguinal bypass with reversed saphenous vein for critical limb ischemia
    Jayer Chung
    Department of Surgery, Vascular Surgery Section, University of Colorado Health Sciences Center, Denver, CO 80262 0302, USA
    J Vasc Surg 43:1183-90. 2006
    ..To examine wound healing and the functional natural history of patients undergoing infrainguinal bypass with reversed saphenous vein for critical limb ischemia (CLI)...
  39. ncbi Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial
    Robert W Schrier
    Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado School of Medicine, Denver, CO 80262, USA
    Nat Clin Pract Nephrol 3:428-38. 2007
    ..Analysis of the results of 5 years of follow-up revealed a highly significant correlation of all-cause and cardiovascular mortality with left ventricular mass and severity of albuminuria...
  40. ncbi Effect of atorvastatin on energy expenditure and skeletal muscle oxidative metabolism at rest and during exercise
    J Chung
    The Colorado Prevention Center, University of Colorado Health Sciences Center, Denver, Colorado, USA
    Clin Pharmacol Ther 83:243-50. 2008
    ..Eight weeks of atorvastatin therapy was not associated with alterations in substrate oxidation, or muscle oxidative function at rest, or during exercise in healthy adults...
  41. ncbi Lack of relationship between gait parameters and physical function in peripheral arterial disease
    Susan A Scherer
    Regis University, University of Colorado Denver, Denver, CO 80221, USA
    J Vasc Surg 44:782-8. 2006
    ..The aims were to evaluate usual and maximal walking speed and gait parameters (step length, cadence and toe out angle) in subjects with PAD-IC and control subjects with similar baseline activity levels...
  42. ncbi Observational studies of drug safety--aprotinin and the absence of transparency
    William R Hiatt
    University of Colorado School of Medicine and Colorado Prevention Center, Denver, USA
    N Engl J Med 355:2171-3. 2006
  43. ncbi Risk assessment in drug development for symptomatic indications: a framework for the prospective exclusion of unacceptable cardiovascular risk
    Eric P Brass
    Department of Medicine, Section of Vascular Medicine, University of Colorado Health Sciences Center, Colorado Prevention Center, and National Jewish Medical and Research Center, Denver, 80203, USA
    Clin Pharmacol Ther 79:165-72. 2006
  44. ncbi Clinical and demographic predictors of exercise capacity in end-stage renal disease
    Kathy E Sietsema
    Department of Medicine, Harbor UCLA Research and Education Institute, Torrance, CA, USA
    Am J Kidney Dis 39:76-85. 2002
    ....
  45. ncbi Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials
    Jeffrey S Berger
    Department of Medicine, Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, USA
    JAMA 301:1909-19. 2009
    ..Despite guideline recommendations for secondary prevention in peripheral artery disease (PAD), the effect of aspirin in this population is not well established...
  46. ncbi Cardiovascular disease mortality in Hispanics and non-Hispanic whites
    Carolyn J Swenson
    Department of Preventive Medicine and Biometrics, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Am J Epidemiol 156:919-28. 2002
    ..43 (95% CI: 0.21, 0.91). A statistically significant decreased risk of CVD death was observed only in male Hispanics with diabetes. Competing mortality or factors that interact with diabetes may explain these differences...
  47. ncbi Pulmonary VO2 dynamics during treadmill and arm exercise in peripheral arterial disease
    Timothy A Bauer
    Section of Vascular Medicine, University of Colorado Health Sciences Center, Box B-179, 4200 East Ninth Ave, Denver, CO 80262, USA
    J Appl Physiol 97:627-34. 2004
    ..Furthermore, the slowed pulmonary Vo(2) kinetics of the lower extremity could not be explained by any abnormalities in resting cardiac or pulmonary function and were not related to the magnitude of reduction in limb vascular reactivity...
  48. ncbi Russian immigrant cardiovascular risk assessment
    P S Mehler
    Denver Health, University of Colorado, USA
    J Health Care Poor Underserved 12:224-35. 2001
    ..00001). Almost half of the participants had two or more cardiac risk factors. Cardiac risk factor identification and intervention programs may help to reduce the health care costs for these patients...
  49. ncbi Lack of improvement in the treatment of hyperlipidemia among patients with type 2 diabetes
    Philip S Mehler
    Denver Health, Denver, Colorado 80204, USA
    Am J Med 114:377-82. 2003
    ..We investigated the adequacy of treatment of hyperlipidemia in patients with type 2 diabetes, and assessed the temporal trends in adherence to published guidelines...
  50. ncbi Dietary sodium restriction rapidly improves large elastic artery compliance in older adults with systolic hypertension
    Phillip E Gates
    Department of Integrative Physiology, University of Colorado, Boulder, CO 80309, USA
    Hypertension 44:35-41. 2004
    ..These improvements in central arterial compliance appear to be a key mechanism in the rapid normalization of SBP by sodium restriction in these patients...
  51. ncbi Design of the Del-1 for therapeutic angiogenesis trial (DELTA-1), a phase II multicenter, double-blind, placebo-controlled trial of VLTS-589 in subjects with intermittent claudication secondary to peripheral arterial disease
    Sanjay Rajagopalan
    Section of Vascular Medicine, Zena and Michael A Wiener Cardiovascular Institute, Mount Sinai School of Medicine, Box 1030, One Gustave Levy Place, New York, NY 10029, USA
    Hum Gene Ther 15:619-24. 2004
    ....
  52. ncbi Blood pressure reductions with exercise and sodium restriction in postmenopausal women with elevated systolic pressure: role of arterial stiffness
    D R Seals
    Department of Kinesiology and Applied Physiology, University of Colorado, Boulder 80309, USA
    J Am Coll Cardiol 38:506-13. 2001
    ....
  53. ncbi Peripheral arterial disease is not associated with an increased prevalence of intradialytic cramps in patients on maintenance hemodialysis
    Eric P Brass
    Department of Medicine, Harbor UCLA Medical Center, Torrance, Calif 90502, USA
    Am J Nephrol 22:491-6. 2002
    ..Peripheral arterial disease (PAD) has been suggested as a contributing factor to the development of intradialytic muscle cramps in patients on maintenance hemodialysis...
  54. ncbi Bridging the quality gap in diabetic hyperlipidemia: a practice-based intervention
    Philip S Mehler
    Department of Internal Medicine and Cardiology Division at Denver Health, Division of Geriatrics, University of Colorado Health Sciences Center, Denver, Colo, USA
    Am J Med 118:1414. 2005
    ..Our aim was to increase the percentage of diabetic patients in whom lipid management was achieved through electronic and direct educational detailing...
  55. ncbi TASC II section F on revascularization in PAD
    Lars Norgren
    Department of Surgery, University Hospital, Orebro, Sweden
    J Endovasc Ther 14:743-4. 2007
  56. ncbi Review of mortality and cardiovascular event rates in patients enrolled in clinical trials for claudication therapies
    Eric P Brass
    Harbor UCLA Center for Clinical Pharmacology, 1124 W Carson Street, Torrance, CA 90502, USA
    Vasc Med 11:141-5. 2006
    ..The current analyses provide benchmark data for ensuring that development programs are large enough to allow meaningful safety conclusions, and to assist in data and safety monitoring of these trials...
  57. ncbi Peripheral arterial disease: medical care and prevention of complications
    David L Dawson
    Uniformed Services University of the Health Sciences, Bethesda, MD, USA
    Prev Cardiol 5:119-30. 2002
    ..When diagnosed early, both exercise and pharmacotherapy can ameliorate symptoms of claudication, augment functional performance, and improve quality of life...
  58. ncbi Is revascularization and limb salvage always the best treatment for critical limb ischemia?
    Mark R Nehler
    J Vasc Surg 37:704-8. 2003
  59. ncbi Treatment of intermittent claudication with beraprost sodium, an orally active prostaglandin I2 analogue: a double-blinded, randomized, controlled trial
    Emile R Mohler
    University of Pennsylvania School of Medicine, Philadelphia Heart Institute, Room 432, 51 North 39th Street, Philadelphia, PA 19104, USA
    J Am Coll Cardiol 41:1679-86. 2003
    ..In the current study, we hypothesized that beraprost would: 1) improve treadmill exercise performance and quality of life; and 2) decrease rates of ischemic events in patients with intermittent claudication...
  60. ncbi Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease
    Emile R Mohler
    Cardiovascular Division, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Circulation 108:1481-6. 2003
    ..When treated with atorvastatin, patients with peripheral arterial disease may experience improvement in symptoms to complement the anticipated reduction in cardiovascular events reported in other studies of statins...
  61. ncbi Sounding the PAD alarm. GPs can diagnose peripheral artery disease with a simple ankle-and-arm blood pressure test
    William R Hiatt
    Health News 10:7. 2004
  62. ncbi Utility and barriers to performance of the ankle-brachial index in primary care practice
    Emile R Mohler
    University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Vasc Med 9:253-60. 2004
    ..The ABI is a simple peripheral arterial disease detection tool that can be successfully applied in primary care office practices...
  63. ncbi A high ankle-brachial index is associated with increased cardiovascular disease morbidity and lower quality of life
    Matthew A Allison
    Department of Family and Preventive Medicine, University of California San Diego, California, USA
    J Am Coll Cardiol 51:1292-8. 2008
    ..The purpose of this study is to determine if an ankle-brachial index (ABI) >or=1.40 is associated with reduced quality of life (QoL)...
  64. ncbi Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia
    Eric P Brass
    Harbor UCLA Medical Center for Clinical Pharmacology, Torrance, California 90502, USA
    J Vasc Surg 43:752-9. 2006
    ..The current trial was designed to test the hypothesis that lipo-ecraprost would improve amputation-free survival in patients with CLI who had no revascularization options...
  65. ncbi Atherosclerotic Vascular Disease Conference: Writing Group III: pathophysiology
    David P Faxon
    Circulation 109:2617-25. 2004
  66. ncbi Why TASC II?
    Lars Norgren
    Vasc Med 12:327. 2007
  67. ncbi Evaluating effects of method of administration on Walking Impairment Questionnaire
    Karin S Coyne
    MEDTAP International, 7101 Wisconsin Avenue, Suite 600, Bethesda, MD 20814, USA
    J Vasc Surg 38:296-304. 2003
    ..Currently this questionnaire is validated for interviewer administration only. Since this can be burdensome in a large clinical trial, we examined the effects of alternative methods of administration on patient responses on the WIQ...
  68. ncbi Managing abnormal blood lipids: a collaborative approach
    Barbara Fletcher
    Circulation 112:3184-209. 2005
    ..Use of this collaborative approach for the treatment of ABL ultimately will improve cardiovascular and cerebrovascular morbidity and mortality...
  69. ncbi Aspirin for prevention of cardiovascular events
    William R Hiatt
    BMJ 337:a1806. 2008
  70. ncbi Peripheral arterial disease in patients with diabetes
    Steven P Marso
    Mid America Heart Institute, University of Missouri Kansas City, Saint Luke s Hospital, Kansas City, Missouri 64111, USA
    J Am Coll Cardiol 47:921-9. 2006
    ..This article will review the clinical implications of the consensus statement and highlight the treatment options available in order to help prevent future ischemic events in diabetic individuals with PAD...
  71. ncbi The effects of vascular disease and aging on the regulation of circulating endothelial progenitor cells
    William R Hiatt
    Vasc Med 11:258. 2006